Value202320242025TTMSelling/general/admin expenses811 M618 M634 M625 MResearch & development106 M108 M97 M91 MOperating income-4 M32 M262 M333 MNon-Operating Income, Total—25 M21 M19 MInterest expense, net of interest capitalized—35 M43 M40 MNon-Operating Income, excl. Interest Expenses—-10 M-22 M-21 MUnusual income/expense————Pretax income1 M14 M239 M295 MEquity in earnings————Taxes-1 M11 M29 M44 MNon-controlling/minority interest————After tax other income/expense—0——Net income before discontinued operations2 M2 M210 M252 MDiscontinued operations————Net income2 M2 M210 M252 MDilution adjustment————Preferred dividends————Diluted net income available to common stockholders—2 M210 M252 MBasic earnings per share (Basic EPS)—0.021.682.01Diluted earnings per share (Diluted EPS)—0.021.641.95Average basic shares outstanding—132 M125 M—Diluted shares outstanding—133 M128 M—EBITDA—61 M729 M338 MEBIT—32 M719 M329 MCost of revenue186 M231 M246 M242 MOther cost of goods sold—36 M26 M—Depreciation & amortization (cash flow)17 M29 M10 M9 M
Indivior Pharmaceuticals, Inc. - Common Stock
Indivior is an American pharmaceuticals company. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, it is focussed on substitution products for opioid addiction. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.